市場調査レポート

商品コード

1084773

肝炎治療薬の世界市場の規模・シェア・展望・機会の分析 (2022年～2028年)：薬剤クラス・疾患タイプ・投与経路・流通チャネル・地域別

Global Hepatitis Drugs Market, By Drug Class, By Disease Type, By Route of Administration, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日: 2022年05月10日 | 発行: Coherent Market Insights

| ページ情報: 英文 173 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,500 700,920円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Multi User License)

USD 7,000 1,090,320円

レポートPDFを7名までにてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は7回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 10,000 1,557,600円

レポートPDFを同一企業およびその子会社のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=155.76円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界的な肝炎の増加が肝炎治療薬市場の成長を後押しすると予想されています。一方で、肝炎治療薬の開発・承認に要する時間の長さなどが予測期間中の市場成長の妨げとなる見通しです。

当レポートでは、世界の肝炎治療薬の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、法規制環境、償還シナリオ、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

Hepatitis refers to an inflammatory condition of the liver. Viral infections of the liver classified as hepatitis include hepatitis A, B, C, D, and E. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are most likely to become ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women which increase maternal and fetal mortality and morbidity.

Market Dynamics

Increasing prevalence of hepatitis worldwide is expected to boost growth of the hepatitis drugs market. According to World Health Organization (WHO), in 2015, 257 million people were living with chronic hepatitis B infection, and in 2016, while 4.5 million (16.7%) of the people were diagnosed with hepatitis B . Hepatitis B can be prevented by safe and effective vaccines. Additionally, the WHO aims for eliminating viral hepatitis infections which include 90% reduction of new infections, 65% reduction in deaths resulting from viral hepatitis infections worldwide by 2030.

However, factors such as longer development and approval time for hepatitis drugs is expected to hinder growth of the hepatitis drugs market during the forecast period. For instance, according to the National Center for Biotechnology Information 2017, the development of a new medicine for hepatitis from target identification through approval for marketing, takes 12 years or longer.

Key features of the study:

This report provides in-depth analysis of the hepatitis drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global hepatitis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global hepatitis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hepatitis drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Hepatitis Drugs Market, By Drug Class:
- Interferon Alphas
- HIV NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
Global Hepatitis Drugs Market, By Disease Type:
- Hepatitis B
- Hepatitis C
- Others
Global Hepatitis Drugs Market, By Route of Administration:
- Oral
- Injection
Global Hepatitis Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Hepatitis Drugs Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
  - By Drug Class:
- Interferon Alphas
- HIV NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
  - By Disease Type:
- Hepatitis B
- Hepatitis C
- Others
  - By Route of Administration:
- Oral
- Injection
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
  - By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
  - By Drug Class:
- Interferon Alphas
- HIV NRTIs
- Hepatitis B NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
  - By Disease Type:
- Hepatitis B
- Hepatitis C
- Others
  - By Route of Administration:
- Oral
- Injection
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
  - By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
  - By Drug Class:
- Interferon Alphas
- HIV NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
  - By Disease Type:
- Hepatitis B
- Hepatitis C
- Others
  - By Route of Administration:
- Oral
- Injection
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
  - By Drug Class:
- Interferon Alphas
- HIV NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
  - By Disease Type:
- Hepatitis B
- Hepatitis C
- Others
  - By Route of Administration:
- Oral
- Injection
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
  - By Drug Class:
- Interferon Alphas
- HIV NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
  - By Disease Type:
- Hepatitis B
- Hepatitis C
- Others
  - By Route of Administration:
- Oral
- Injection
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
  - By Country:
- South Africa
- Central Africa
- North Africa
  - By Drug Class:
- Interferon Alphas
- HIV NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
  - By Disease Type:
- Hepatitis B
- Hepatitis C
- Others
  - By Route of Administration:
- Oral
- Injection
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Company Profiles
- Merck & Co. Inc.*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Gilead Sciences Inc.
- AbbVie Inc.
- Bristol Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- LAURUS Labs
- Zydus Cadila
- Hetero Healthcare Limited
- GlaxoSmithKline PLC
- Cipla Inc.

"*" marked represents similar segmentation in other categories in the respective section

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Landscape
Epidemiology Analysis
Reimbursement Scenario
PEST Analysis

4. Global Hepatitis Drugs Market, By Drug Class, 2017 - 2028 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028(%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Interferon Alphas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
HIV NRTIs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Nucleotide Polymerase / NS5A Inhibitor Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Hepatitis C Protease / NS5A Inhibitor Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
NS5A Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Nucleotide Polymerase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Nucleoside Analogue Antivirals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Thrombopoiesis Stimulating Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

5. Global Hepatitis Drugs Market, By Disease Type, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028(%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hepatitis B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Hepatitis C
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Hepatitis Drugs Market, By Route of Administration, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028(%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Hepatitis Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028(%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global Hepatitis Drugs Market, By Region, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2028(%)
- Y-o-Y Growth Analysis, By Region, 2017 - 2028
- Regional Trends
North America
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.S.
- Canada
Europe
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Africa
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- North Africa
- Central Africa
- South Africa
Middle East
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)l
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East

9. Competitive Landscape

Company Profiles
- Merck & Co. Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Gilead Sciences Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bristol Myers Squibb Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- LAURUS Labs
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Zydus Cadila
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Hetero Healthcare Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GlaxoSmithKline PLC.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Cipla Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
Analyst Views

10. Section

References
Research Methodology
About Us and Sales Contact

肝炎治療薬の世界市場の規模・シェア・展望・機会の分析 (2022年～2028年)：薬剤クラス・疾患タイプ・投与経路・流通チャネル・地域別

Global Hepatitis Drugs Market, By Drug Class, By Disease Type, By Route of Administration, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章調査目的・前提条件

第2章市場概要

第3章市場力学・法規制・動向分析

第4章世界の肝炎治療薬市場：薬剤クラス別

第5章世界の肝炎治療薬市場：疾患タイプ別

第6章世界の肝炎治療薬市場：投与経路別

第7章世界の肝炎治療薬市場：流通チャネル別

第8章世界の肝炎治療薬市場：地域別

第9章競合情勢

第10章セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objective and Assumption

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Hepatitis Drugs Market, By Drug Class, 2017 - 2028 (US$ Million)

5. Global Hepatitis Drugs Market, By Disease Type, 2017 - 2028, (US$ Million)

6. Global Hepatitis Drugs Market, By Route of Administration, 2017 - 2028, (US$ Million)

7. Global Hepatitis Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Million)

8. Global Hepatitis Drugs Market, By Region, 2017 - 2028, (US$ Million)

9. Competitive Landscape

10. Section

肝炎治療薬の世界市場の規模・シェア・展望・機会の分析 (2022年～2028年)：薬剤クラス・疾患タイプ・投与経路・流通チャネル・地域別

Global Hepatitis Drugs Market, By Drug Class, By Disease Type, By Route of Administration, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章 調査目的・前提条件

第2章 市場概要

第3章 市場力学・法規制・動向分析

第4章 世界の肝炎治療薬市場：薬剤クラス別

第5章 世界の肝炎治療薬市場：疾患タイプ別

第6章 世界の肝炎治療薬市場：投与経路別

第7章 世界の肝炎治療薬市場：流通チャネル別

第8章 世界の肝炎治療薬市場：地域別

第9章 競合情勢

第10章 セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objective and Assumption

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Hepatitis Drugs Market, By Drug Class, 2017 - 2028 (US$ Million)

5. Global Hepatitis Drugs Market, By Disease Type, 2017 - 2028, (US$ Million)

6. Global Hepatitis Drugs Market, By Route of Administration, 2017 - 2028, (US$ Million)

7. Global Hepatitis Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Million)

8. Global Hepatitis Drugs Market, By Region, 2017 - 2028, (US$ Million)

9. Competitive Landscape

10. Section

第1章調査目的・前提条件

第2章市場概要

第3章市場力学・法規制・動向分析

第4章世界の肝炎治療薬市場：薬剤クラス別

第5章世界の肝炎治療薬市場：疾患タイプ別

第6章世界の肝炎治療薬市場：投与経路別

第7章世界の肝炎治療薬市場：流通チャネル別

第8章世界の肝炎治療薬市場：地域別

第9章競合情勢

第10章セクション